Birmingham, AL, United States of America

V Satish Kumar

This inventor holds 31 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignee: Biocryst Pharmaceuticals, Inc.. Active years: 2009-2024.

USPTO Granted Patents = 31 (Patent Applications = 13)

% Patents Active = 96.8

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 6.3

ph-index = 10

Forward Citations = 405(Granted Patents)

Company Filing History:

31 out of 92

Biocryst Pharmaceuticals, Inc.

patents

Years Active: 2009-2024

Loading Chart...

Areas of Expertise:

Human Plasma Kallikrein Inhibitors

ALK2 Kinase Inhibitors

Complement Inhibitors

Prodrugs of Kallikrein Inhibitors

Antiviral Nucleoside Analogs

Hepatitis C Therapies

Therapeutic Furopyrimidines

Thienopyrimidines

Antiviral Therapeutic Agents

9-Deazapurine Derivatives

RNA Viral Polymerases

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12162838 - Human plasma kallikrein inhibitors (2024-12-10),

2. 12116346 - Human plasma kallikrein inhibitors (2024-10-15),

3. 12054492 - Imidazole-containing inhibitors of ALK2 kinase (2024-08-06),

4. 12043610 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2024-07-23),

5. 11866418 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2024-01-09),

6. 11807605 - Human plasma kallikrein inhibitors (2023-11-07),

7. 11708347 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2023-07-25),

8. 11708333 - Human plasma kallikrein inhibitors (2023-07-25),

9. 11708332 - Human plasma kallikrein inhibitors (2023-07-25),

10. 11685721 - Human plasma kallikrein inhibitors (2023-06-27),

11. 11661426 - Imidazole-containing inhibitors of ALK2 kinase (2023-05-30),

12. 11618731 - Prodrugs of kallikrein inhibitors (2023-04-04),

13. 11370774 - Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors (2022-06-28),

14. 11230530 - Human plasma kallikrein inhibitors (2022-01-25),

15. 11203574 - Human plasma kallikrein inhibitors (2021-12-21),

Title: V Satish Kumar: Innovator in Human Plasma Kallikrein Inhibitors

Introduction

V Satish Kumar, based in Birmingham, AL, is a noteworthy inventor with a remarkable portfolio of 31 patents. His innovative work primarily focuses on the domain of human plasma kallikrein inhibitors, contributing significantly to the field of biopharmaceuticals.

Latest Patents

Among his latest patents, Kumar has disclosed compounds that encapsulate the formula I of human plasma kallikrein inhibitors. These advancements represent a critical step in the development of therapeutic interventions for a variety of medical conditions.

Career Highlights

Kumar has significantly impacted the biopharmaceutical industry through his tenure at reputable companies, including BioCryst Pharmaceuticals, Inc. His extensive career is marked by his contributions to pioneering research and development, establishing him as a prominent figure in the field.

Collaborations

Throughout his career, Kumar has worked alongside esteemed colleagues such as Pravin L. Kotian and Yarlagadda Sudhakara Babu. Their collaborative efforts have surely enhanced the innovation process, fostering an environment where groundbreaking ideas can flourish.

Conclusion

In conclusion, V Satish Kumar's contributions through his patents and collaborations underscore his role as a key innovator in the biopharmaceutical field. His work on human plasma kallikrein inhibitors exemplifies the impact that dedicated inventors can have on advancing medical science and improving patient outcomes.